Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : email@example.com
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Unknown unknown||clear cell renal cell carcinoma||not applicable||Everolimus + Vorolanib||Phase I||Actionable||In a Phase I trial, Vorolanib (X-82) and Afinitor (everolimus) combination therapy was well tolerated, and resulted in an objective response rate of 32% (6/19) and a disease control rate of 100% in patients with advanced clear cell renal cell carcinoma, with a median progression-free survival of 5.6 months (PMID: 32335374; NCT03095040).||32335374|